9MW 1911
Alternative Names: 9MW-1911Latest Information Update: 14 Oct 2025
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin-33 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic obstructive pulmonary disease
- No development reported Asthma; Atopic dermatitis
Most Recent Events
- 30 Sep 2025 Adverse events, pharmacokinetics and immunogenicity data from a phase I trial in volunteers released by Mabwell (Shanghai) Bioscience
- 30 Sep 2025 Pharmacodynamics data from a preclinical trial in Chronic obstructive pulmonary disease released by Mabwell (Shanghai) Bioscience
- 28 Jan 2025 No recent reports of development identified for phase-I development in Asthma(In the elderly, In volunteers, In adults) in China (IV, Injection)